Precedent-setting perspective on current bankruptcy and restructuring situations, plus weekly takes on companies that will likely be in need of advisory assistance.
The vice chair and head of M&A discusses building the firm's biotech practice, helping Covid-19 vaccine developer Moderna grow over the years and recent transformational deals in the latest episode of the podcast.
Poor governance and issues with executive compensation aren't enough to warrant credible activist involvement on their own, but they can serve as a lever for shareholders that have broader outcomes in mind, says Shane Goodwin, the chief of the Applied Corporate Governance Institute.
This website uses cookies to ensure you get the best experience on our website. Read MoreACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.